GeneArt / Life Technologies Inc.


    • Company type:
      • Research & Development
      • Service Provider
    • Year founded:
    • 1999
    • Employees (at the site):
    • 190
    • Turnover range:
    • not available
    • Products/services:
    • GeneArt offers integrated system solutions for the development of DNA and protein based biopharmaceutical products and is the partner for outsourcing of complex life science projects, such as the following:
      Products for Synthetic Biology: Kit systems for the higher order assembly of synthetic genes or functional biobricks to e.g. subgenomic or genomic DNA sequences
      Custom Gene Synthesis & Services: Optimization and synthesis of genes, biobricks or complete genomes
      Directed Evolution: Target-oriented design of gene variants, gene libraries and their production based on an optimized master gene
      Plasmid Services: Insertion of synthesized genes, gene variants or gene libraries into plasmid vectors and production of the desired quantity and quality (up to cGMP)
      Cell Lines and Proteins: Protein production from stable or transiently transfected mammalian cell lines as well as functional testing of cell lines and proteins

    • Core competencies:
    • Since entering the Gene Synthesis market in 2000, GeneArt has established itself as a global market leader. Today the company is an upfront specialist in the area of Synthetic Biology. GeneArt provides key technologies for the development and production of biopharmaceuticals and vaccines and for the modification of bacteria, yeasts and blue algae that synthesize industrial enzymes, fine chemicals, agricultural products or even bio-ethanol and bio-diesel from organic waste or degrade environmental toxins. Since December 2010, GeneArt is a 100% subsidiary of the US-based Life Technologies Corporation.

    • Language skills:
    • English
    • Key Tech / section:
      • Biotechnology: Agrobiotechnology for plants
      • Biotechnology: Prophylactic drug development
      • Biotechnology: Technical services for biotechnology
      • Biotechnology: Therapeutic drug development
    • Industries NACE:
      • 72: Scientific research and development
    • Certification:
    • DIN EN ISO 9001

    • Sales markets - target industries:
    • not available
    • Sales markets - target countries:
    • not available
    • Cooperation offers:
    • not available
    • Contact person:
    • Piet van der Zande (Mr.)
      - Management

      Johannes Lämmel (Mr.)
      - Management

      Prof. Dr. Ralf Wagner (Mr.)
      - Research & development